Alembic Pharmaceuticals Ltd Stock Analysis

BSE: 533573 | NSE: APLLTD | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 29-Sep-2023 18:02
783.90 20.75 (2.72%)

DeciZen - Make an Informed Decision on Alembic Pharma

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Semi Strong

Alembic Pharma Price Chart

P/E Ratio (CD):
Market Cap:
15,408.6 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is Alembic Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Alembic Pharmaceuticals Ltd is a good quality company.

2. Is Alembic Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Alembic Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Alembic Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alembic Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Alembic Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alembic Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 33.1%29.1%50.3%22.2%15.9%17.2%19.8%20.9%8.7%21.8%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,8632,0563,1663,1353,1313,9354,6065,3935,3065,6535,877
YoY Gr. Rt. %-10.4%54%-1%-0.1%25.7%17.1%17.1%-1.6%6.5%-
Adj EPS 12.614.83821.620.730.245.255.324.858.526.9
YoY Gr. Rt. %-17.9%156.6%-43.1%-4.3%46.2%49.6%22.6%-55.2%136.1%-
BVPS (₹) 35.846.984.7100.9117.8144.2170.8257.8266.5222.4228.5
Adj Net Profit 2372797154073895698511,0884871,149529
Cash Flow from Ops. 2401729483293128124491,463552724-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%12.5%7.1%6.5%
Adj EPS 18.7%23.1%9%136.1%
Share Price 18.6% 4.3% -5.4% 29.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 40.235.757.723.318.92328.726.39.523.911.9
Op. Profit Mgn % 19.419.231.819.819.721.826.427.416.512.615.2
Net Profit Mgn % 12.713.622.613.112.714.717.919.69.220.39
Debt to Equity
Working Cap Days 1631681331591941821781741921880
Cash Conv. Cycle 3947162632386970881050

Recent Performance Summary

Sales growth is good in last 4 quarters at 12.47%

Return on Equity has declined versus last 3 years average to 11.90%

Sales growth has been subdued in last 3 years 7.07%

Net Profit has been subdued in last 3 years 9.00%

Latest Financials - Alembic Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 25.1 26.9
TTM Sales (₹ Cr.) 5,304 5,877
BVPS (₹.) 229.5 228.5
Reserves (₹ Cr.) 4,473 4,452
P/BV 3.42 3.42
PE 31.21 29.11
From the Market
52 Week Low / High (₹) 463.30 / 825.00
All Time Low / High (₹) 34.00 / 1150.00
Market Cap (₹ Cr.) 15,409
Equity (₹ Cr.) 39.3
Face Value (₹) 2
Industry PE 42.8

Management X-Ray of Alembic Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Alembic Pharma

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Alembic Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Alembic Pharma on 29-Sep-2023 18:02 is : 783.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Sep-2023 18:02 the market cap of Alembic Pharma stood at ₹ 15,408.6.
The latest PE ratio of Alembic Pharma as of 29-Sep-2023 18:02 is 31.21.
The latest PB ratio of Alembic Pharma as of 29-Sep-2023 18:02 is 3.42
The 52-week high of Alembic Pharma is ₹ 825.0 and the 52-week low is ₹ 463.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Alembic Pharma is ₹ 5,304 ( Cr.) .

About Alembic Pharmaceuticals Ltd

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'


  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now